Samuel C. Fehling

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors

Aubrey L. Miller, Samuel C. Fehling, Patrick L. Garcia et al. · EBioMedicine · 2019 · 106 citations · Full text

Medicine, Cancer Biology, Oncology +17

Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma

Rajani Rajbhandari, Braden C. McFarland, Ashish Patel et al. · Oncotarget · 2015 · 48 citations · Full text

Medicine, Cancer Biology, Oncology +17

The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma

Samuel C. Fehling, Aubrey L. Miller, Patrick L. Garcia et al. · Cancer Letters · 2019 · 36 citations · Full text

Medicine, Oncology, Pharmacology +11

Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma

Braden C. McFarland, Margaret P. Marks, Amber L. Rowse et al. · Oncotarget · 2016 · 31 citations · Full text

Life Sciences, Immunology, Oncology +17

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

Aubrey L. Miller, Patrick L. Garcia, Samuel C. Fehling et al. · Cancers · 2021 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17